# Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease

> **NCT04358081** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Covid-19

## Interventions

- **DRUG:** HCQ
- **DRUG:** HCQ+AZT
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04358081
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-01
- **Primary completion:** 2020-07-27
- **Final completion:** 2020-07-27
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04358081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04358081, "Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04358081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*